TTVR tidlig gennemførlighedsundersøgelse
Den tidlige gennemførlighedsundersøgelse af Transkateter Tricuspid Valve Replacement System Transfemoral System
The objective of this early feasibility study is to gain early clinical insight into the performance of the Intrepid transcatheter tricuspid valve replacement (TTVR) system intended for transfemoral access to deliver a self-expanding bioprosthetic valve within the tricuspid valve.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
Multi-center, prospective, non-randomized, investigational, and pre-market.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
Alabama
-
Birmingham, Alabama, Forenede Stater, 35233
- University of Alabama at Birmingham (UAB) Hospital
-
-
Arizona
-
Phoenix, Arizona, Forenede Stater, 85016
- Abrazo Arizona Heart Hospital
-
-
California
-
Los Angeles, California, Forenede Stater, 90048
- Cedars Sinai Medical Center
-
San Francisco, California, Forenede Stater, 94115
- California Pacific Medical Center
-
-
Connecticut
-
Hartford, Connecticut, Forenede Stater, 06102
- Hartford Hospital
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30308
- Emory University Hospital Midtown
-
-
Michigan
-
Ann Arbor, Michigan, Forenede Stater, 48109
- University of Michigan Health System - University Hospital
-
Grand Rapids, Michigan, Forenede Stater, 49503
- Corewell Health
-
-
Minnesota
-
Minneapolis, Minnesota, Forenede Stater, 55407
- Abbott Northwestern Hospital
-
-
Montana
-
Missoula, Montana, Forenede Stater, 59802
- Providence Saint Patrick Hospital
-
-
New York
-
New York, New York, Forenede Stater, 10029
- The Mount Sinai Hospital
-
New York, New York, Forenede Stater, 10032
- New York-Presbyterian Hospital Columbia University Medical Center
-
The Bronx, New York, Forenede Stater, 10467
- Montefiore Medical Center
-
-
Ohio
-
Cincinnati, Ohio, Forenede Stater, 45242
- The Christ Hospital
-
Cleveland, Ohio, Forenede Stater, 44106
- University Hospitals Cleveland Medical Center
-
Columbus, Ohio, Forenede Stater, 43214
- OhioHealth Riverside Methodist Hospital
-
-
Oregon
-
Portland, Oregon, Forenede Stater, 97239
- Oregon Health & Science University Hospital
-
-
Pennsylvania
-
Harrisburg, Pennsylvania, Forenede Stater, 17101
- UPMC Pinnacle Harrisburg Campus
-
-
Texas
-
Houston, Texas, Forenede Stater, 77030
- Houston Methodist Hospital
-
-
Wisconsin
-
Milwaukee, Wisconsin, Forenede Stater, 53125
- Aurora Saint Lukes Medical Center
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Heart Team agrees that patient is deemed symptomatic despite medical therapy (including obligatory diuretic) and a candidate for bioprosthetic tricuspid valve replacement
- Subject is at an intermediate or greater estimated risk of mortality with tricuspid valve surgery as determined by the local Heart Team
- Subjects with severe symptomatic primary and / or secondary tricuspid regurgitation determined by the Echocardiography Core Lab assessment of a qualifying transthoracic echocardiogram (TTE) and transesophageal echocardiogram (TEE)
- New York Heart Association (NYHA) Function Class II or greater
- Subject anatomically suitable for the Intrepid TTVR delivery system including transfemoral access
- Subject and the treating physician agree that the subject will return for all required post-procedure follow-up visits
- Subject meets the legal minimum age to provide informed consent based on local regulatory requirements
Exclusion Criteria:
- Estimated life expectancy of less than 24 months due to associated non-cardiac co-morbid conditions
- Anatomic contraindications for Intrepid™ TTVR (e.g., annular dimensions)
- Evidence of intracardiac mass, inferior vena cava, or femoral venous mass or thrombus
- Implanted with venous stents (iliac and/or femoral) or inferior vena cava (IVC) filter or congenital abnormalities of the IVC that would preclude ability for transfemoral access of delivery system
- Echocardiographic evidence of severe right ventricular dysfunction
- Left ventricular ejection fraction (LVEF) <30 as measured by resting echocardiogram within 30 days of the Index Procedure
- Need for emergent or urgent surgery
- Untreated clinically significant coronary artery disease requiring revascularization
- Carcinoid tricuspid regurgitation
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Primary Cohort
Device: Intrepid TTVR System |
Device: Intrepid™ TTVR System |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Rate of implant or delivery related serious adverse events
Tidsramme: Through 30 days post-procedure
|
Rate of implant or delivery related serious adverse events |
Through 30 days post-procedure
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Successful access, delivery of implant, and retrieval of the delivery system assessed by definitions per Mitral Valve Academic Research Consortium (MVARC)
Tidsramme: During Procedure
|
For procedural success to be present, device success must have been achieved without major clinical complications as detailed per clinical trial design principles and endpoint definitions for transcatheter mitral valve repair and replacement (part 2: endpoint definitions) |
During Procedure
|
|
Change in TR Grade from baseline
Tidsramme: Through 30 days post-procedure
|
Change in TR Grade from baseline |
Through 30 days post-procedure
|
|
Rate of no significant TV stenosis
Tidsramme: Through 30 days post-procedure
|
Rate of no significant TV stenosis |
Through 30 days post-procedure
|
|
Change in NYHA Class from baseline
Tidsramme: Through 30 days post-procedure
|
Change in NYHA Class from baseline |
Through 30 days post-procedure
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- MDT20009TMV003
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .